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Abstract
The human immunodeficiency virus (HIV) was first detected in 1982 among homosexual 
men, and subsequently, it was further detected in various regions of world. In 2016, WHO 
estimated that 36.7 million people were living with HIV, 1.9 million were newly infected HIV 
patients and approximately 1 million people died worldwide. HIV attacks CD4 T cells and 
causes immunodeficiency. Weakened immune system of HIV patients increases the oppor-
tunity to acquire various infections caused by fungi, bacteria, parasites and other viruses. 
Bacterial infections that cause huge threats to HIV patients are tuberculosis, syphilis, bacte-
rial enteric diseases and bacterial pneumonia. Important bacterial etiologies are Streptococcus 
pneumoniae, Salmonella spp. Haemophilus influenzae, Staphylococcus aureus, Citrobacter freun-
dii, Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Pseudomonas aeruginosa and 
Mycobacterium tuberculosis. Frequent bacterial infections in HIV patients increase the usage 
and also highly expose bacteria to antibiotics. Most problematic multidrug-resistant bacte-
ria are extended-spectrum β-lactamases producing P. aeruginosa, Acinetobacter baumannii, E. 
coli and K. pneumoniae; vancomycin-resistant enterococci; methicillin-resistant S. aureus and 
multidrug-resistant and extensively drug-resistant M. tuberculosis. These antibiotic-resistant 
bacteria complicate the treatment of infections in HIV patients with available antibiotics 
and sometimes cause death. It also causes higher medical costs, prolonged hospital stays, 
increased mortality and economic burden on families and societies.
Keywords: HIV patients, multidrug resistant, vancomycin-resistant enterococci, 
methicillin-resistant Staphylococcus aureus, antibiotic resistance
1. Introduction
Human immunodeficiency virus (HIV) is a lentivirus belongs to the family of Retroviridae 
and it causes Acquired Immunodeficiency Syndrome (AIDS) in an advanced stage of HIV 
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infection. HIV was first detected in 1981 among homosexual men in the New York City who 
had unusual clusters of Pneumocystis jirovecii pneumonia and Kaposi sarcoma [1, 2]. After that, 
HIV positivity was detected in the various regions globally and actively spread in the com-
munity with increased rate of HIV infection. In 2016, the World Health Organization (WHO) 
has reported that HIV continues to be a major global public health issue, having claimed 
more than 35 million lives so far. One million people died from HIV-related causes; further-
more, approximately 36.7 million people are living with HIV and 1.8 million people becoming 
newly infected worldwide. African region is the most affected area with 25.6 million people 
living with HIV in 2016. It accounts for almost two-thirds of the global total number of new 
HIV infections [3, 4].
HIV spreads from one person to another by sexual contact such as vaginal sex, anal sex and oral 
sex and also spreads by sharing injection equipment, getting tattoos or body piercings with 
unsterilized needles, accidental needle sticks, contaminated blood transfusions and splashing 
blood in eyes. HIV can pass from HIV-positive pregnant women to their babies in the womb 
and during birth. It can also be transferred to other persons through certain body fluids such 
as blood, semen, vaginal fluid and breast milk [5]. After entry into the human body system, 
HIV infects vital immune cells such as helper T cells (specifically CD4+ T cells), macrophages 
and dendritic cells [6]. Hence, HIV infection leads to low level of CD4+ T cells through three 
important mechanisms. First mechanism is direct viral killing of the infected cells; second 
is increased rate of apoptosis in infected cells; and third is killing of infected CD4+ cells by 
CD8 cytotoxic lymphocytes. Virus multiplication declines the number of CD4+ cells below a 
critical level; therefore, the cell mediated immunity is lost and the weaken immune system 
signal to various opportunistic infections (OIs) and cancers [6–9]. Compromised immune 
system of HIV patients increases the chances of acquiring various OIs caused by fungi, bac-
teria, parasites and other viruses based on the CD4 cell counts. Tuberculosis (TB) generally 
develops at CD4 count of 200–500 cells/mm3, as does Candida albicans infection Pneumocystis 
jirovecii pneumonia (PCP, earlier known as Pneumocystis carinii) occurs at CD4 count <200 
cells/mm3 and cytomegalovirus (CMV) infection occurs when the CD4 count falls below 100 
cells/mm3 [10]. As compared to other microbes, bacteria cause high rate of infections such 
as tuberculosis, syphilis, bacterial enteric diseases, pneumonia and bartonellosis. Bacteria 
causing various infections associated with HIV patients include Streptococcus pneumoniae, 
Salmonella spp., Haemophilus influenzae, Staphylococcus aureus, Citrobacter freundii, Escherichia 
coli, Klebsiella pneumoniae, Morganella morganii, Pseudomonas aeruginosa, Mycobacterium tuber-
culosis and Mycobacterium avium complex, and they have emerged as an important cause of 
morbidity and mortality in HIV individuals [11, 12].
High frequency of bacterial infections in HIV patients increases the chance of consumption 
of high level of antibiotics. Over usage and mishandling of antibiotics develop various resis-
tance mechanisms among bacteria. The dramatic increase in the incidence of multidrug-
resistant (MDR) bacteria and transfer of resistance from one organism to another make 
bacterial infections more difficult to treat with current antibiotics, so the treatment options 
are often extremely limited [13]. This chapter describes about various bacterial diseases and 
antibiotic-resistant bacteria from HIV patients.
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2. Bacterial infections among HIV patients
2.1. Respiratory tract infections
Respiratory tract infection (RTI) is defined as infectious disease of upper or lower respi-
ratory tract of human body system. RTI is classified as an upper respiratory tract infec-
tion and a lower respiratory tract infection. Pneumonia is an infection in one or both side 
of lungs causing inflammation in the air sacs (alveoli). In this condition, alveoli fill with 
phlegm (mucus) or pus making difficult to breathe. Bacterial pneumonia is a common cause 
of HIV-related morbidity with the symptoms of body chills, rigors, pleuritic chest pain and 
purulent sputum, fever, tachypnea, tachycardia, rales or rhonchi and other signs. Incidence 
of bacterial respiratory infections among HIV-positive population has been reported 
approximately 90 cases per 1000 per year, which is higher than noninfected population [14]. 
Bacterial pneumonia among HIV infection was 7.8 times more likely to develop bacterial 
pneumonia than HIV sero-negative persons. The count of CD4+ T lymphocyte is the most 
consistent predictor of bacterial infections and other factors are also involved that include 
qualitative B-cell defects (reduced ability to produce antibody), impaired neutrophil func-
tion or both and non-HIV related factors such as cigarette smoking, use of crack cocaine, 
IDU, alcoholism, or liver diseases [15, 16]. The causative of bacterial pneumonia among 
persons with HIV has been relative prominence of Streptococcus pneumoniae followed by 
Haemophilus influenzae, Pseudomonas aeruginosa and Staphylococcus aureus. Some studies 
encountered Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae that 
are causative organisms for atypical pneumonia. S. pneumoniae infection is 15–300 times 
more common among HIV individuals than among age-matched non-HIV individuals and 
also rate of recurrent pneumococcal pneumonia is 8–25% within 6 months. The second 
most common cause of bacterial pneumonia is H. influenza and in an advanced immuno-
suppression, S. aureus and P. aeruginosa can cause invasive pneumonias, sometimes associ-
ated with bacteremia. HIV patients ill over a period of weeks to months are more likely to 
have Pneumocystis jirovecii pneumonia, tuberculosis (caused by Mycobacterium tuberculosis) 
or chronic fungal infection.
2.2. Enteric infections
Rates of Gram-negative bacterial enteric infections are at least 10 fold higher among HIV 
infected persons than in the general population. Risk of bacterial enteric infections varies 
according to CD4 T-cell with the count of <200CD4 cells/mm3. The common causes of bacterial 
diarrhea among persons with HIV are Salmonella (Salmonella enterica serotypes Typhimurium 
and Enteritidis), Campylobacter and Shigella species. Patients with HIV are at increased risk for 
developing salmonellosis and they have the incidence rates of salmonellosis as 20–100 folders 
higher than the non-HIV patients. Campylobacter jejuni has been reported among HIV patients 
particularly men who have sex with men (MSM) with the incidence rate of 39 times higher 
than general population. Other than these infections, Shigella bacteremia is more common 
among HIV patients and might occur in both mild and severe cases of clinical shigellosis. 
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The major clinical syndromes of salmonellosis among person with HIV infection include a 
self-limited gastroenteritis; a more severe and prolonged diarrheal disease, associated with 
fever, bloody diarrhea and weight loss and Salmonella septicemia, which might present with 
or without gastrointestinal symptoms. Sometimes, bacteremia can occur with each of these 
syndromes and is more likely to occur among those with advanced immunosuppression. 
Diarrheagenic E. coli, particularly enteroaggregative E. coli also contribute to the burden of 
diarrheal disease. The lower CD4 cell count of <50 cells/mm3 is an independent risk factor for 
Clostridium difficile associated infection (CDI) among HIV population [15].
2.3. Urinary tract infections
The urinary tract system of human is divided into two major divisions such as upper 
urinary tract (kidneys, renal pelves and ureters) and lower urinary tract (urinary blad-
der and urethra). Urinary tract infections (UTIs) are an infection in any part of urinary 
system, but most UTIs occur in lower urinary tract especially bladder (cystitis). Women 
are at high risk of developing a UTIs then men. UTIs occur when bacteria enter and infect 
the urinary tract and sometimes spread to the kidneys (pyelonephritis) [17]. UTIs are one 
of the significant illnesses that cause clinical burden among HIV individuals. It is the most 
common nosocomial infection [7] and cause high rate of morbidity [18]. HIV disease is 
associated with a variety of renal syndromes in patients with low CD4+ cell counts, causing 
neurologic complications such as bladder areflexia and hyporeflexia, which lead to urinary 
stasis and ultimately infection [19, 20]. Once a patient’s CD4+ T-cell count falls below 200 
cell/mm3, the individual is then at risk of a variety of opportunistic infection. The most 
predominant causative organisms are encapsulated bacteria which include Streptococcus 
pneumoniae and Haemophilus influenzae, but non-typhoidal Salmonella, Staphylococcus aureus 
and Pseudomonas aeruginosa have also been implicated. Among opportunistic infections, 
UTI accounts for 60% of AIDS defining illness [21]. Signs and symptoms of UTIs are pain or 
burning while urinating, frequent urination, feeling urinate even having an empty bladder, 
fever (less than 101°F), cloudy and bloody urine and pressure or cramping in the groin or 
lower abdomen [22].
2.4. Bloodstream infections
Even reduction of AIDS-related deaths and opportunistic infections after introduction of 
combined antiretroviral therapy (cART), infection with HIV causes the increased risk of 
bloodstream infection (BSI). It is a frequent complication found in HIV-infected patients 
and is usually associated with a poor prognosis, responsible for the immediate cause of 
death up to 32% of HIV-infected patients, especially under particular conditions (e.g., intra-
venous drug abuse, use of a central venous catheter (CVC), neutropenia, and a low CD4 
T-cell count) [23]. BSI is associated with increased mortality rate, length of hospital stay and 
intensive care unit (ICU) admission rate, and it is more frequent cause of ICU admission 
than Pneumocystis jirovecii pneumonia in HIV-infected patients. In majority of cases, the 
BSI is due to bacterial pathogens. The infectious agents begin infecting almost any part 
of any organ (from skin, lung [pneumonia], gastrointestinal tract [bacterial penetration or 
ruptured intestine from trauma]) or through implanted devices (surgical instruments, intra-
venous catheter, etc.).
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The infecting microorganisms or their toxins spread directly or indirectly into the blood-
stream that allows spreading from infection site to any other organ system. Common bacte-
rial causes of BSI are nontyphoidal salmonella, Streptococcus pneumoniae, Escherichia coli and 
Staphylococcus aureus are the most important pathogens of BSI. Fungal and mycobacterial 
infections are less frequent but have considerable clinical and economic impact. Among the 
pathogens responsible for BSI, Mycobacteria spp., Cryptococcus neoformans and recurrent non-
typhoidal salmonella constitute AIDS-defining conditions [24]. Symptoms of BSI are altered 
mental status (altered consciousness, mental confusion or delirium), fast respiratory rate, low 
blood pressure, elevated heart rate (tachycardia), fever, body chills, dizziness, fatigue, shiver-
ing, facial flushing, skin discoloration, shock and sleepiness.
2.5. Syphilis
Syphilis is a bacterial infection caused by Treponema pallidum which is usually spread by 
sexual contact and associated with an increased risk of sexual acquisition and transmis-
sion of HIV. The disease starts as a painless sore-typically on genitalis, rectum and mouth. 
Direct contact with sores would spread syphilis from person to person, and the bacteria 
enter through minor cuts and abrasions in the skin or mucous membrane. It is contagious 
during its primary and secondary and early syphilis can be cured sometimes with a single 
dose of penicillin. Clinical manifestations of syphilis are similar to persons without HIV 
infection, difference is genital lesions may be more apparent and accelerated progression of 
disease seen in HIV population. Syphilis has various stages like primary syphilis, second-
ary syphilis and latent syphilis. The symptoms are small bumps or tumors called gummas, 
which develop on skin, bones, liver or any other organ in the late stage of syphilis. It also 
causes some neurological problems such as stroke, meningitis, hearing loss, visual problems, 
dementia, loss of pain and temperature sensations and sexual dysfunction in men, bladder 
incontinence and sudden lightning like pains along with fever, malaise, anorexia, arthralgias 
and headache. It may also cause inflammation of the aorta and miscarriage, can transfer from 
mother to fetus [15].
2.6. Tuberculosis
Tuberculosis (TB) is a potentially serious infectious disease mainly affects lungs. TB is 
mainly caused by Mycobacterium tuberculosis (MTB) and also caused by other organisms of 
Mycobacterium tuberculosis complex—M. bovis, M. africanum, M. canetti, and M. microti [25]. 
TB can also attack any part of the body including kidneys, spine and brain. TB is spread 
from person having lung TB to another person through the air, while cough, sneeze or spit. 
Transmission of TB occurs when a person inhales droplet nuclei containing M. tuberculosis, 
the droplet nuclei traverse the mouth or nasal passages, upper respiratory tract and bron-
chi to reach the alveoli of the lungs. In 2010, there were 8.8 (8.5–9.2 million) incident cases 
of TB, 1.1 million (0.9–1.2 million) deaths from TB among HIV-negative people and other 
0.35 million deaths from HIV associated TB. In 2016, there were an estimated 10.4 million 
new cases of tuberculosis (TB) worldwide. Seven countries accounted for 64% of the total, 
with India leading the count, followed by Indonesia, China, Philippines, Nigeria, Pakistan 
and South Africa. A total of 1.7 million people died from TB in 2016 (0.4 million people 
with HIV) [26].
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Two types of TB conditions exist: latent TB infection and TB disease. (1) Latent TB infection: 
Among persons with latent TB infection (LTBI), bacteria present in the body in an inactive 
state and cause no symptoms. It is also called inactive TB or TB infection; it has positive reac-
tion to tuberculin skin rest or TB blood test. Persons with LTBI are not infectious and do not 
spread TB infection to others. Chest X-ray would be normal and negative sputum test, they 
do not feel sick. (2) TB disease: The symptoms of TB disease include feel of sickness or weak-
ness, weight loss, fever and night swears, coughing, chest pain, and coughing up of blood. 
The signs and symptoms of active TB include coughing (lasts three or more weeks), coughing 
up blood, chest pain or pain with breathing or coughing, unintentional weight loss, fatigue, 
fever, night sweats, body chills and loss of appetite. Tuberculosis in spine may develop back 
pain and in kidneys might cause blood in urine.
3. Bacterial resistance to antibiotics
Antibiotics are natural microbial drugs used for the treatment and control of bacterial infec-
tions. First time the antibiotic penicillin was discovered by Fleming [27] while examining 
some colonies of Staphylococcus aureus. He observed that Staphylococcus colonies became trans-
parent and undergo lysis around a large colony of mold. Finally, he identified that mold as 
penicillium and concluded that certain types of penicillium produced a powerful antibacterial 
substance that acts against pyogenic cocci and the diphtheria bacilli. Since the discovery of 
penicillin, many other antibiotics have been discovered or developed. Antibiotics may either 
kill or inhibit the growth of the bacteria and they are commonly classified based on their 
mechanism of action, chemical structure and spectrum of activity. Penicillins, cephalosporins 
and carbapenems are cell wall synthesis inhibitors, polymyxins are cell membrane synthesis 
inhibitors, rifamycins, lipiarmycins, quinolones, and sulfonamides interfere with the activ-
ity of essential bacterial enzymes and macrolides, lincosamides and tetracyclines are protein 
synthesis inhibitors [28]. The time line of antibiotic discovery was given in Table 1.
Antibiotic resistance is the ability of bacteria to resist the effects of drugs previously used to 
treat them [13]. Resistant bacteria are more difficult to treat, requiring alternative medications 
or higher doses, both of which may be more expensive or more toxic. Microbes resistant to 
multiple antimicrobials are called multidrug resistant (MDR); those extensively drug resis-
tant (XDR) or totally drug resistant (TDR) are sometimes called “superbugs.” Bacteria have 
various drug-resistant mechanisms contributing toward inactivation of antibiotics [30, 31] 
following as
• novel penicillin-binding proteins (PBPs),
• enzymatic mechanisms of drug modification,
• mutated drug targets,
• enhanced efflux pump expression and
• altered membrane permeability.
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3.1. Factors influencing emergence of drug resistance
Various factors are involved in the emergence of antibiotic drug-resistant bacteria, the factors 
are inappropriate usage of antibiotics, patient movement within and between medical institu-
tions, infection control measures, travel of people and food stuffs, antibiotic residues in the 
environment, dose duration and treatment, cross selection, gene transfer and clonal spread 
and socioeconomic factors [31]. The time line of development of antibiotic resistance was 
presented in Table 2.
3.2. β-Lactamases
The production of β-lactamase enzymes is the most common mechanism of bacterial resis-
tance to β-lactam antibiotics such as the penicillins and cephalosporins. These enzymes cata-
lyze the hydrolysis of the β-lactam ring to create ineffective antimicrobials. β-Lactamases were 
first identified in Staphylococcus aureus strains in the late 1940s, prior to the introduction of 
penicillin into the clinical setting [46]. Some β-lactamases are having substrate specificities 
relatively narrow and these are often traditionally referred as penicillinases or cephalospori-
nases. Over 400 β-lactamases have been reported to date, and new β-lactamases continue to 
Timeline Antibiotics Resistance
>1910 Salvarsan —
1921–1930 Penicillin; Prontosil —
1940–1050 Gramicidin; Neomycin; Streptomycin; Bacitracin; Nitrofurans; 
Chloramphenicol; Polymyxin; Chlortetracycline; Cephalosporin
Sulfonamide; Penicillin;
Spectinomycin; Bacitracin;
Chloramphenicol;
Streptomycin
1950–1960 Erythromycin; Isoniazid; Vancomycin; Virginiamycin; Cycloserine; 
Novobiocin; Kanamycin; Rifamycin; Metronidazole
Macrolide; Tetracycline;
Neomycin; Nalidixic acid
1960–1970 Methicillin; Ampicillin; Nalidixic acid;
Trimethoprim; Fusidic acid, Fosfomycin; Actinomycin D; 
Lincomycin
Methicillin; Cephalosporin;
Polymyxin; Rifamycin;
Vancomycin; Erythromycin;
Kanamycin
1970–1990 Gentamicin; Mupirocin; Azithromycin; Carbapenem; Imipenem; 
Ciprofloxacin; Oxazolidinone
Metronidazole; Ampicillin;
Gentamycin; Carbapenem
1990–2010 Linezolid; Telithromycin; Daptomycin; Tigecycline; Retapamulin; 
Garenoxacin; Telavancin; Besifloxacin; Ce-aroline fosamil
Imipenem; Ciprofloxacin;
Mupirocin; Azithromycin;
Linezolid; Daptomycin;
Tigecycline
2010–2016 Fidaxomicin; Bedaquiline; Teixobactin —
Table 1. Timeline of antibiotic discovery and emergence of antimicrobial resistance [29].
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Infections, Reference/
Country
Isolated bacteria Drug resistance
RTI (Peru)
[32]
M. tuberculosis MDR-TB -43%
Isoniazid resistance – 4%;
Isoniazid, rifampicin and pyrazinamide – 32%;
Isoniazid, rifampicin, ethambutol, streptomycin 
and pyrazinamide – 14%
UTI (India)
[33]
Escherichia coli, 10.3%
S. aureus, 5%
K. pneumoniae, 4%
E. faecalis, 2%,
P. aeruginosa 1%
Proteus spp .1%
S. epidermidis, 1%
Amp, ctx, cip, sxt-33.3%; amp, ctx, cip, nit, 
sxt- 27.8%
BSI (Combodia)
[34]
Escherichia coli, 30.7%
S. choleraesuis, 11.4%
Nontyphoidal
Salmonella spp. 6.8%
S. typhi, 2.3%
Klebsiella spp. 5.7%
Enterobacter spp 3.4%
B. pseudomallei, 2.3%
Pseudomonas sp. 3.4%
Acinetobacter sp.2. 9%
S. aureus, 19.3%
Streptococcus suis, 1.1%
Enterococci, 1.1%
E. coli: amx-96%; cot-80%; cip-61%; amc-57%; 
ctr-46%; gen-57%
S. typhi: cip-100%; amx and cot-50%
Nontyphoidal Salmonella spp.: amx-80%; cot-
60%; cip-40%
S. aureus: oxa-28%; cot-28%
UTI (India)
[35]
E. coli, 100% FQ resistance: 77.6%; ESBL and AmpC-71.1%
ESBL-3.9%
RTI (India)
[36]
M. tuberculosis MDR-TB – 38%;XDR-TB- 6%; Mono-resistant 
TB - 21%; Poly-resistant TB – 12%;
Extremely drug-resistant TB – 2%
UTI and WI
(Tanzania)
[37]
E. coli, 56%;
K. pneumoniae, 37%
S. aureus, 72%
Proteus spp. 43%
P. aeruginosa, 38%
Cot-75%; amc-34%; cip-33.3%; amp-86.4%;  
cro-66.7%; tet-81.3%; ery-27.3%
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Infections, Reference/
Country
Isolated bacteria Drug resistance
UTI (Nigeria) [38] E. coli, 30%
K. pneumoniae, 14.2%
P. aeruginosa, 27.6%
S. aureus, 28.3%
E. coli: caz-95.2%; oxa-92.8%; amp-88%; chl-73.8%; 
cro-69%; tet-50%; nit-45.2%; cot & ery-42.9%
UTI & BSI (India)
[39]
E. coli, 51%
K. pneumoniae, 14.6%
K. oxytoca, 12.6%
P. aeruginosa, 11.2%
Proteus mirabilis, 7.3%
P. vulgaris, 2.6%
Ery-99%; amp-94%; cpd-91%; atm-90%; cfp & 
fox-89.4%; pip-85.4%; caz-84.8%; cro-74.2%; ipm-
73.5%; tzp-72.4%; tet-66.9%; cip-66.2%; dox-58.2%
Nasopharynx colonization
(Ghana)
[40]
M. catarrhalis, 39.8%;
Coagulase negative staphylococci, 
33.1%;
S. pneumoniae, 30.5%;
Diphtheroids, 29.7%;
Viridian streptococci, 27.1%;
S. aureus, 22%;
Citrobacter spp. 4.2%;
M. catarrhalis: amp-80%; CoT-60%; mrp-42.6%; 
chl-23%
S. aureus: pcn-100%; tet-80%; cfx-73%; ery-38%
S. pneumoniae: cot-58%; tet-33%; ery-33%; 
oxa-27%
EI(Cameroon)
[41]
E. coli, 85.3%
Klebsiella spp. 29.4%
Enterobacter spp. & Citrobacter 
spp. 23.5%
Salmonella sp. 5.9%
Serratia sp. 1.5%
Proteus sp. 2.9%
E. coli: amx-60.3%; amc-62%; cro-39.6%;  
chl-32.7%; dox-91.3%
Klebsiella spp: amx, amc – 100%; dox-70%; 
tet-50%; chl-35
Enterobacter spp: amx, amc-93.7%; dox-87.5%; 
tet-63.8%; chl and cip-37.5%
Citrobacter sp.: amx, amc, cro-43.7%; dox-68.7%; 
tet-30%
Salmonella spp.: dox & chl-75%
Serratia spp: amx, amc, chl & dox- 100%
UTI (India)
[42]
E. coli, 50.7%
K. pneumoniae, 13.2%
K. oxytoca, 11.8%
P. mirabilis, 6.3%
P. vulgaris, 1.4%
P. aeruginosa, 5.5%
Azt-94.6%; cpd-93.8%; cefoperazone-91.3%,  
fox-90.3%; ctx-89%, amp-89%, ipm-72%
Enterobacteriaceae- ESBL-52.5%; MBL & 
AmpC- 62.5%
P. aeruginosa- ESBL-50%; MBL and AmpC-62.5%
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emerge rapidly worldwide [47, 48]. β-Lactamase producing organisms pose a major problem 
for clinical therapeutics. The incidence of β- lactamase producing strains among clinical has 
been steadily increasing over the past few years resulting in limitation of therapeutic options. 
β-Lactamases are classified based on the molecules (Ambler Classification) and functions 
(Bush-Jacoby-Medeiros classification) of the enzymes [49]. Most important β-lactamase 
enzymes are extended spectrum β-lactamases (ESBLs), AmpC β- lactamase (AmpC) and 
Metallo β-lactamase (MBL).
Infections, Reference/
Country
Isolated bacteria Drug resistance
UTI (Tanzania)
[43]
E. coli, 57.7%
K. pneumoniae, 23.1%
C. freundii, 3.9%
S. aureus, 3.9%
P. agglomerans, 1.9%
S. agalactiae, 1.9%
E. coli: amp-93.3%; sxt-90%; amc-43.3%;
K. pneumoniae: amp-100%; sxt-72.7%; nit-33.3%; 
amc-54.5%
RTI (China)
[44]
P. aeruginosa, 24.1%
E. coli, 16%
A. baumannii, 15.1%
K. pneumoniae, 13.4%
Stenotrophomonas maltophilia, 11.6%
S. aureus, 4.4%
S. pneumoniae, 1.8%
Tuberculosis-19.3%
MRSA-3%; VRE-1%; ESBL-62%;
Multidrug resistant TB-22%
Extensively drug-resistant TB-3.5%
OM (Tanzania)
[45]
P. aeruginosa, 6.4%
E. coli, 5.3%
K. oxytoca, 5%
K. pneumoniae, 12.4%
S. aureus, 45.7%
M. catarrhalis, 3.2%
P. mirabilis, 1.1%
S. epidermidis, 5.0%
S. pneumoniae, 2.5%
P. aeruginosa: amp-73.3%; amc-53.3%; ery-40%
E. coli: amp & fox- 51.4%; ery-45.9%
K. oxytoca: ery-62.5%; fox-50%; amp-43.8%
K. pneumoniae: amp-51.2%; amc-48.6%
S. aureus: amp-46.5%; fox-42.7%; ery-37.4%
M. catarrhalis: amk & amp-55.6%
P. mirabilis: ery-100%; amc & amp- 66.7%
S. epidermidis: ery-64.3%; fox-55.5%; amp-50%
S. pneumoniae: ery-71.4%; fox-42.9%
S. pyogenes: amp-48.7%; ery-42.1%
RTI: respiratory tract infections; BSI: blood stream infection; UTI: urinary tract infection; WI: wound infection; EI: enteric 
infection; OM: Otitis Media; amk – amikacin; amx – amoxicillin; amc - amoxicillin-clavulanic acid; amp – ampicillin; 
ctx – cefotaxime; fox – cefoxitin; cpd – cefpodoxime; caz – ceftazidime; cro – ceftriaxone; chl – chloramphenicol; cip – 
ciprofloxacin; dox – doxycycline; ery – erythromycin; gen – gentamicin; ipm – imipenemmem – meropenem; nit – 
nitrofurantoin; oxa – oxacillin; pen – penicillin; pip – piperacillin; tzp - piperacillin-tazobactam; tmp – trimethoprim; 
sxt - trimethoprim-sulfamethoxazole.
Table 2. Bacterial infections and drug resistance in HIV patients.
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4. Drug-resistant bacteria from HIV patients
Human immunodeficiency virus (HIV)-infected individuals are highly vulnerable to a various 
opportunistic infections (OIs) due to their compromised immune system. For the prophylaxis 
of OIs, HIV patients are frequently exposed to high level of antimicrobial agents which leads to 
the emergence of multidrug-resistant bacteria. MDR bacteria become a major problem in the 
clinical management of HIV disease. Treatment of common bacterial infections like acute respi-
ratory tract infections, urinary tract infections, wound infections, meningitis, and blood stream 
infections are very difficult when they are associated with MDR bacteria leading to increased 
morbidity and mortality. Multidrug resistant (MDR) pathogens are relentlessly multiplying 
in HIV patients and thus become an important circulating source of infection in the commu-
nity. Globally, very few scientific data are available on the drug-resistant bacteria from HIV 
population.
Co-trimoxazole (also called as trimethoprim-sulfamethoxazole (TMP-SMX)) is a broad-spec-
trum antibiotic, used as a prophylactic agent against opportunistic infections among HIV/AIDS 
patients. Especially, TMP-SMX is an active drug against Pneumocystis pneumonia (PCP) caused 
by Pneumocystis jirovecii among HIV-infected patients [50, 51]. World Health Organization 
and Joined Nations Programme on HIV/AIDS have recommended TMP-SMX prophylaxis 
for immunosuppressed adults and children born to HIV-infected women [52–54]. Long-term 
receiving of TMP-SMX prophylaxis has lead to increase in the development of TMP-SMX-
resistant bacteria, which spreading in the bacterial community and cause therapeutic problems 
for bacterial infections in HIV population. In Enterobacteriaceae, sulfonamide drug resistance 
genes such as sul1, sul2, and sul3 are responsible for dihydropteroate synthases, and more than 
20 dihydrofolate reductase (dfr) genes conferring resistance to trimethoprim [55] (Table 2).
UTI accounts for consumption of large proportion of anti-bacterial drugs [18]. Resistance to 
commonly prescribed antibiotics for UTI is an expanding global problem both in developed as 
well as developing countries [56]. UTI became quite alarming as isolated uropathogens exhibit 
high percentage resistance to almost all antibiotics [57]. The pattern of antibacterial susceptibility 
of UTI causing pathogen has been changing over the years, and the drug resistant of the bacteria 
is influenced by the extensive and misuse of antibiotics and changing patient population, espe-
cially among immunocompromised patients. β-Lactam antibiotics such as penicillins, cephalo-
sporins and carbapenems are the most commonly used antibacterial drugs. The predominant 
drug resistance mechanisms against β-lactam antibiotics among Gram-negative bacteria are the 
production of Extended Spectrum β-lactamases (ESBLs) and AmpC β-lactamases [58] and they 
are associated with increased morbidity and mortality with immunocompromised individu-
als. The frequency of Pseudomonas aeruginosa and Staphylococcus aureus as community-acquired 
pathogens is higher in HIV-infected individuals than in those not HIV infected. Methicillin-
resistant Staphylococcus aureus (MRSA) infection should be considered as a potential etiology for 
pneumonia, given that community outbreaks of MRSA have been seen in men who have sex 
with men and nasal carriage of MRSA is more common in HIV-infected individuals, particu-
larly at lower CD4 cell counts. Multidrug resistance (MDR) bacteria like ESBL producers and 
MRSA are a major public health concern worldwide [21, 39] (Table 2).
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WHO has documented that MDR-TB is emerging as a major challenge for tuberculosis con-
trol programs and is becoming extensively widespread today throughout the world, even 
in high-income countries with low TB incidence. Resistance to anti-TB drugs occurs due to 
misuse of drugs such as patients do not compete full course of treatment, wrong treatment 
provide by physicians, wrong dose or length of time for taking the drugs and supply of poor 
quality drugs. Multidrug-resistant TB is caused by Mycobacterium tuberculosis that is resistant 
to at least to two most potent TB drugs such as isoniazid and rifampicin. Extensively drug-
resistant TB (XDR-TB) is MTB resistant to isoniazid and rifampicin along with any fluoroqui-
nolone and at least one of three injectable second-line drugs includes amikacin, kanamycin 
or capreomycin. Treatment options for XDR-TB have more side effects, and they are more 
expensive. XDR-TB can weaken the immune system, and persons are more likely to develop 
TB disease and they are at high risk of death.
In 2010, about 650,000 cases have MDR-TB, which account for 5% of all newly diagnosed TB 
patients, and more than 150,000 MDR-TB deaths are estimated to occur worldwide each year 
with case fatality rate of 30 per 100 individuals [59]. The proportion of MDR-TB reported 
globally ranges from 0 to 28.3% and 0 to 61.6% among new TB cases and among previously 
treated TB cases respectively [60]. People living with HIV are at a higher risk of developing 
MDR and XDR tuberculosis associated with increased mortality, and greatly reduced survival 
time of patients [61] (Table 2).
5. Future impact of antimicrobial resistance
The two multidisciplinary research teams such as RAND Europe and KPMG, have provided 
their own high-level assessments of the future impact of antimicrobial resistance, based on 
scenarios for rising drug resistance and economic growth to 2050. The studies estimate 300 
million people are expected to die prematurely due to drug resistance over the next 35 years 
and the world’s Gross Domestic Product (GDP) will be 2% to 3.5% lower than it otherwise 
would be in 2050. This means that between now and 2050, the world can expect to lose between 
60 and 100 trillion USD worth of economic output if antimicrobial drug resistance is not tack-
led. This is equivalent to the loss of around 1 year’s total global output over the period, and 
will create significant and widespread human suffering. Furthermore, in the nearer term, they 
expect the world’s GDP to be 0.5% smaller by 2020 and 1.4% smaller by 2030 with more than 
100 million people having died prematurely [62].
6. Tackle of antimicrobial resistance
WHO developed a global priority of pathogens list (global PPL) of antibiotic-resistant bacteria 
to help in prioritizing the research and development (R&D) of new and effective antibiotic 
treatments. Drug-resistant bacteria were categorized into critical priority, high priority and 
medium priority pathogens (Table 3) [63].
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7. Global action plan, WHO
WHO developed the global action plan with five strategic objectives to achieve the goal of 
ensuring continuity of successful treatment and prevention of infectious diseases with effec-
tive and safe medicines [64]. They (1) improve the awareness and understanding of antimi-
crobial resistance through effective communication, education and training, (2) strengthen 
the knowledge and evidence base through surveillance and research, (3) reduce the incidence 
of infection through effective sanitation, hygiene and infection prevention measures, (4) opti-
mize the use of antimicrobial medicines in human and animal health and (5) develop the 
economic case for sustainable investment that takes account of the needs of all countries, and 
increase investment in new medicines, diagnostic tools, vaccines and other interventions.
7.1. Examples for global impact of antimicrobial resistance research and 
interventions
Examples of global research into antimicrobial resistance and its impact are given below [29]:
• Chinese Ministry of Health in 2011, reduced unnecessary prescription of antimicrobials by 
10–12%.
• The Swedish Strategic Programme against Antibiotic Resistance (STRAMA): decrease in 
antibiotic use for outpatients from 15.7 to 12.6 daily doses per 1000 inhabitants and from 
536 to 410 prescriptions per 1000 inhabitants per year from 1995 to 2004. The decrease was 
most evident for macrolides (65%).
• WHO essential medicines policies: reductions in antibiotic use of ≥20% in upper respira-
tory tract infections and 30% of reduction in the use of antibiotics in acute diarrheal illness.
• Antimicrobial stewardship programme (2009–2014) in 47 South African hospitals: reduc-
tion of antibiotic doses daily per 100 patient days from 101.4 to 83.04.
Type of priority List of drug-resistant pathogens
Critical priority Carbapenem-resistant Acinetobacter baumannii; Carbapenem-resistant Pseudomonas 
aeruginosa; Carbapenem-resistant, 3rd generation cephalosporin-resistant 
Enterobacteriaceae
Medium priority Penicillin-non-susceptible Streptococcus pneumonia; Ampicillin-resistant 
Haemophilus influenza; Fluoroquinolone-resistant Shigella spp.
High priority Vancomycin-resistant Enterococcus faecium; Methicillin-resistant, Vancomycin-
intermediate and resistant Staphylococcus aureus
Clarithromycin -resistant Helicobacter pylori; Fluoroquinolone-resistant 
Campylobacter; Fluoroquinolone-resistant Salmonella spp.
3rd generation cephalosporin-resistant, fluoroquinolone-resistant Neisseria 
gonorrhoeae
Table 3. Global priority of pathogens list by World Health Organization.
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• Antimicrobial Resistance Monitoring and Research Programme (United States): Infections 
with carbapenem-resistant Enterobacteriaceae declined and there were no further reports 
of outbreaks of colistin-resistant Acinetobacter spp.
• In the Netherlands, a decrease of CTX-M−1-1-like ESBL genes (from 44 to 25%) in livestock 
was seen during 2010–2014 due to >60% reduction in antibiotic use in livestock.
8. Conclusion(s)
Spread of antibiotic-resistant bacteria is leading to untreatable infections causing a major pub-
lic health threat. Handling of new approaches such as combination therapeutics, organism 
specific drugs and repurposing of antibiotics might helpful in the treatment of drug-resistant 
bacterial infections on stipulated time and reduce the burden in clinical settings. Effective 
global investments are needed to improve the way prevent, control and monitor the emer-
gence and global spread of drug resistance.
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